Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

Christina Fitzmaurice, Christine A. Allen, Ryan M Barber, +176

JAMA Oncology

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

Arvind Dasari, Chan Shen, Daniel M. Halperin, +5

JAMA Oncology

The Global Burden of Cancer 2013

Christina Fitzmaurice, Daniel Dicker, Amanda Pain, +124

JAMA Oncology

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017

Christina Fitzmaurice, Degu Abate, Naghmeh Abbasi, +607

JAMA Oncology

The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level

Tomi Akinyemiju, Semaw Ferede Abera, Muktar Beshir Ahmed, +78

JAMA Oncology

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

David A. Reardon, Alba A. Brandes, Antonio Omuro, +17

JAMA Oncology

Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma

Yuri E. Nikiforov, Raja R. Seethala, Giovanni Tallini, +28

JAMA Oncology

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim, +18

JAMA Oncology

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

Kohei Shitara, Eric Van Cutsem, Yung‐Jue Bang, +25

JAMA Oncology

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer

Ryan Phillips, William Y. Shi, Matthew P. Deek, +23

JAMA Oncology